References
- Merle P. The new immuno-oncology-based therapies and their perspectives in hepatocellular carcinoma. Cancers. 2021;13(2):238. doi:https://doi.org/10.3390/cancers13020238. PubMed PMID: 33440630; PubMed Central PMCID: PMCPMC7826922.
- Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–53. doi:https://doi.org/10.1053/j.gastro.2015.12.041.
- Genard G, Lucas S, Michiels C. Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies. Front Immunol. 2017;8:828. doi:https://doi.org/10.3389/fimmu.2017.00828. PubMed PMID: 28769933; PubMed Central PMCID: PMCPMC5509958.
- Li Z, Wu T, Zheng B, Chen L. Individualized precision treatment: targeting TAM in HCC. Cancer Lett. 2019;458:86–91. doi:https://doi.org/10.1016/j.canlet.2019.05.019.
- Wei R, Zhu WW, Yu GY, Wang X, Gao C, Zhou X, et al. S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma. Int J Cancer. 2021;148(5):1233–44. doi:https://doi.org/10.1002/ijc.33371.
- Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. 2019;68(9):1653–66. doi:https://doi.org/10.1136/gutjnl-2019-318419.
- Yin C, Han Q, Xu D, Zheng B, Zhao X, Zhang J. SALL4-mediated upregulation of exosomal miR-146a-5p drives T-cell exhaustion by M2 tumor-associated macrophages in HCC. Oncoimmunology. 2019;8(7):1601479. doi:https://doi.org/10.1080/2162402X.2019.1601479. PubMed PMID: 31143524; PubMed Central PMCID: PMCPMC6527304.
- Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer. Nat Rev Genet. 2016;17(12):719–32. doi:https://doi.org/10.1038/nrg.2016.134.
- Hannafon BN, Ding WQ. Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci. 2013;14(7):14240–69. doi:https://doi.org/10.3390/ijms140714240. PubMed PMID: 23839094; PubMed Central PMCID: PMCPMC3742242.
- Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang G, et al. Effect of exosomal miRNA on cancer biology and clinical applications. Mol Cancer. 2018;17(1):147. doi:https://doi.org/10.1186/s12943-018-0897-7. PubMed PMID: 30309355; PubMed Central PMCID: PMCPMC6182840.
- Jang JY, Lee JK, Jeon YK, Kim CW. Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization. BMC Cancer. 2013;13:421. doi:https://doi.org/10.1186/1471-2407-13-421. PubMed PMID: 24044575; PubMed Central PMCID: PMCPMC3848851.
- Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA. 2012;109(31):E2110–E2116. doi:https://doi.org/10.1073/pnas.1209414109. PubMed PMID: 22753494; PubMed Central PMCID: PMCPmc3412003.
- Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, et al. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst. 2015;107(7):135. doi:https://doi.org/10.1093/jnci/djv135. PubMed PMID: 25972604; PubMed Central PMCID: PMCPMC4651042.
- Wang CQ, Sun HT, Gao XM, Ren N, Sheng YY, Wang Z, et al. Interleukin-6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via up-regulating osteopontin expression. Am J Cancer Res. 2016;6(9):1873–89. PubMed PMID: 27725896; PubMed Central PMCID: PMCPMC5043100.
- Xie Y, Ma X, Chen L, Li H, Gu L, Gao Y, et al. MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis. Sci Rep. 2017;7(1):5619. doi:https://doi.org/10.1038/s41598-017-05801-3. PubMed PMID: 28717125; PubMed Central PMCID: PMCPMC5514092.
- Sabarimurugan S, Madhav MR, Kumarasamy C, Gupta A, Baxi S, Krishnan S, et al. Prognostic value of MicroRNAs in Stage II colorectal cancer patients: a systematic review and meta-analysis. Mol Diagn Ther. 2020;24(1):15–30. doi:https://doi.org/10.1007/s40291-019-00440-y.
- Zhang ZQ, Meng H, Wang N, Liang LN, Liu LN, Lu SM, et al. Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma. Diagn Pathol. 2014;9(1):135. PubMed PMID: 24993656; PubMed Central PMCID: PMCPMC4226970. doi:https://doi.org/10.1186/1746-1596-9-135.
- Dong Q, Zhu X, Dai C, Zhang X, Gao X, Wei J, et al. Osteopontin promotes epithelial-mesenchymal transition of hepatocellular carcinoma through regulating vimentin. Oncotarget. 2016;7(11):12997–3012.
- Welsbie DS, Mitchell KL, Jaskula-Ranga V, Sluch VM, Yang Z, Kim J, et al. Enhanced functional genomic screening identifies novel mediators of dual leucine zipper kinase-dependent injury signaling in neurons. Neuron. 2017;94(6):1142–54 e6. doi:https://doi.org/10.1016/j.neuron.2017.06.008. PubMed PMID: 28641113; PubMed Central PMCID: PMCPMC5553555.
- Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–80. doi:https://doi.org/10.1593/neo.07112. PubMed PMID: 17356713; PubMed Central PMCID: PMCPMC1813932.
- Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci. 2018;5(12):181006. PubMed PMID: 30662724; PubMed Central PMCID: PMCPMC6304123. doi:https://doi.org/10.1098/rsos.181006.
- Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer. 2012;19(2):197–208. doi:https://doi.org/10.1530/ERC-11-0329.
- Győrffy B, Surowiak P, Budczies J, Lánczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLos One. 2013;8(12):e82241. PubMed PMID: 24367507; PubMed Central PMCID: PMCPMC3867325. doi:https://doi.org/10.1371/journal.pone.0082241.
- Szász AM, Lánczky A, Nagy Á, Förster S, Hark K, Green JE, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(31):49322–33. doi:https://doi.org/10.18632/oncotarget.10337. PubMed PMID: 27384994; PubMed Central PMCID: PMCPMC5226511.
- Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:https://doi.org/10.1093/nar/gkx247. PubMed PMID: 28407145; PubMed Central PMCID: PMCPMC5570223.
- Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e10. doi:https://doi.org/10.1158/0008-5472.CAN-17-0307. PubMed PMID: 29092952; PubMed Central PMCID: PMCPMC6042652.
- Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7. doi:https://doi.org/10.1186/1471-2105-14-7. PubMed PMID: 23323831; PubMed Central PMCID: PMCPMC3618321.
- Khalaf K, Hana D, Chou JT-T, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol. 2021;12:656364. doi:https://doi.org/10.3389/fimmu.2021.656364.
- Chen Y, Tian Z. HBV-induced immune imbalance in the development of HCC. Front Immunol. 2019;10:204. doi:https://doi.org/10.3389/fimmu.2019.02048. PubMed PMID: 31507621; PubMed Central PMCID: PMCPMC6718466.
- Minguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, et al. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol. 2011;55(6):1325–31. doi:https://doi.org/10.1016/j.jhep.2011.02.034. PubMed PMID: 21703203; PubMed Central PMCID: PMCPMC3624094.
- Erstad DJ, Tanabe KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 2019;26(5):1474–93. doi:https://doi.org/10.1245/s10434-019-07227-9.
- Byun JS, Yi HS. Hepatic immune microenvironment in alcoholic and nonalcoholic liver disease. Biomed Res Int. 2017;2017:6862439. doi:https://doi.org/10.1155/2017/6862439. PubMed PMID: 28852648; PubMed Central PMCID: PMCPMC5567444.
- Zhang Q, Lou Y, Bai XL, Liang TB. Immunometabolism: a novel perspective of liver cancer microenvironment and its influence on tumor progression. World J Gastroenterol. 2018;24(31):3500–12. doi:https://doi.org/10.3748/wjg.v24.i31.3500. PubMed PMID: 30131656; PubMed Central PMCID: PMCPMC6102497.
- Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol. 2014;26:78–88. doi:https://doi.org/10.1016/j.semcancer.2014.01.004. PubMed PMID: 24457013; PubMed Central PMCID: PMCPMC4048791.
- Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):396. doi:https://doi.org/10.1186/s13046-019-1396-4. PubMed PMID: 31500650; PubMed Central PMCID: PMCPMC6734524.
- Granito A, Muratori L, Lalanne C, Quarneti C, Ferri S, Guidi M, et al. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment. World J Gastroenterol. 2021;27(22):2994–3009. doi:https://doi.org/10.3748/wjg.v27.i22.2994.
- Deng L, Huang S, Chen B, Tang Y, Huang F, Li D, et al. Tumor-linked macrophages promote HCC development by mediating the CCAT1/Let-7b/HMGA2 signaling pathway. Onco Targets Ther. 2020;13:12829–43. doi:https://doi.org/10.2147/OTT.S283786. PubMed PMID: 33363387; PubMed Central PMCID: PMCPMC7751845.
- Zhou D, Luan J, Huang C, Li J. Tumor-associated macrophages in hepatocellular carcinoma: friend or foe? Gut Liver. 2020;2020:20223. doi:https://doi.org/10.5009/gnl20223.
- Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019;18(1):64. doi:https://doi.org/10.1186/s12943-019-0976-4. PubMed PMID: 30927925; PubMed Central PMCID: PMCPMC6441214.
- Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39–51. doi:https://doi.org/10.1016/j.cell.2010.03.014. PubMed PMID: 20371344; PubMed Central PMCID: PMCPMC4994190.
- Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80. doi:https://doi.org/10.1002/hep.29086.
- Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–905. doi:https://doi.org/10.1056/NEJMoa1915745.
- Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–70. PubMed PMID: 32716739; PubMed Central PMCID: PMCPMC7479760. doi:https://doi.org/10.1200/JCO.20.00808.
- Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, et al. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol. 2021;14:17562848211016959. doi:https://doi.org/10.1177/17562848211016959. PubMed PMID: 34104211; PubMed Central PMCID: PMCPMC8165525.
- Bickeboller M, Tagscherer KE, Kloor M, Jansen L, Chang-Claude J, Brenner H, et al. Functional characterization of the tumor-suppressor MARCKS in colorectal cancer and its association with survival. Oncogene. 2015;34(9):1150–1159. doi:https://doi.org/10.1038/onc.2014.40.
- Chen CH, Statt S, Chiu CL, Thai P, Arif M, Adler KB, et al. Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications. Am J Respir Crit Care Med. 2014;190(10):1127–38. doi:https://doi.org/10.1164/rccm.201408-1505OC. PubMed PMID: 25318062; PubMed Central PMCID: PMCPMC4299640.
- Chen CH, Cheng CT, Yuan Y, Zhai J, Arif M, Fong LW, et al. Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment. Oncotarget. 2015;6(17):15194–208. doi:https://doi.org/10.18632/oncotarget.3827. PubMed PMID: 26015406; PubMed Central PMCID: PMCPMC4558145.
- Yang Y, Chen Y, Saha MN, Chen J, Evans K, Qiu L, et al. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma. Leukemia. 2015;29(3):715–26. doi:https://doi.org/10.1038/leu.2014.255.
- Wenzel T, Buch T, Urban N, Weirauch U, Schierle K, Aigner A, et al. Restoration of MARCKS enhances chemosensitivity in cancer. J Cancer Res Clin Oncol. 2020;146(4):843–58. doi:https://doi.org/10.1007/s00432-020-03149-2. PubMed PMID: 32056006; PubMed Central PMCID: PMCPMC7085482.
- Techasen A, Loilome W, Namwat N, Duenngai K, Cha’on U, Thanan R, et al. Opisthorchis viverrini-antigen induces expression of MARCKS during inflammation-associated cholangiocarcinogenesis. Parasitol Int. 2012;61(1):140–4. doi:https://doi.org/10.1016/j.parint.2011.07.004.
- Manai M, Abdeljaoued S, Goucha A, Adouni O, Bettaieb I, Bouzaien H, et al. MARCKS protein overexpression is associated with poor prognosis in male breast cancer. Cancer Biomark. 2019;26(4):513–22. doi:https://doi.org/10.3233/CBM-190637.
- Chen CH, Fong LWR, Yu E, Wu R, Trott JF, Weiss RH. Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target. Oncogene. 2017;36(25):3588–98. doi:https://doi.org/10.1038/onc.2016.510. PubMed PMID: 28166200; PubMed Central PMCID: PMCPMC5926797.